Korean J Obstet Gynecol.  2004 Jun;47(6):1071-1079.

Growth Inhibition of Human Uterine Leiomyoma Cells by Selective Estrogen Receptor Modulator

Affiliations
  • 1Department of Obstetrics and Gynecology, School of Medicine, Keimyung University, Daegu, Korea.
  • 2Department of Physiology, School of Medicine, Keimyung University, Daegu, Korea.

Abstract


OBJECTIVE
Our purpose was to evaluate potential efficacy of selective estrogen receptor modulators (raloxifene and tamoxifen) to human uterine leiomyoma cells.
METHODS
The samples were collected from ten hysterectomized specimen. we evaluated the estrogen-responsive growth of human uterine leiomyoma and normal myometrial cells. The potential efficacy of Selective Estrogen Receptor Modulators (SERMs: raloxifene and tamoxifen) to human uterine leiomyoma cells were conducted by MTS, cell count assay and Western-blot.
RESULTS
Human uterine leiomyoma and normal myometrial cells that expressed estrogen receptor (ER) showed increases the cell number in the presence of estrogen compared with ER negative uterine leiomyoma cells. Raloxifene and tamoxifen inhibited estrogen-stimulated proliferation of ER-containing human uterine leiomyoma and normal myometrial cells. Raloxifene was more effective in inhibiting estrogen-induced increases of cell number compared with tamoxifen.
CONCLUSION
The effect of SERMs on leiomyoma was inhibited the cell proliferation without apoptosis or cell cycle arrest. These data suggest that SERM should be examined as candidate of nonsurgical therapeutic agents for uterine leiomyoma.

Keyword

Uterine myoma; SERM

MeSH Terms

Apoptosis
Cell Count
Cell Cycle Checkpoints
Cell Proliferation
Estrogens
Humans*
Leiomyoma*
Raloxifene Hydrochloride
Selective Estrogen Receptor Modulators*
Tamoxifen
Estrogens
Selective Estrogen Receptor Modulators
Tamoxifen
Full Text Links
  • KJOG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error